Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/03/20
End: 11/21/22
Due: 11/21/23
Phase: N/A
Priority: Normal
Start: 06/12/18
End: 06/14/20
Due: 06/14/21
Phase: N/A
Priority: Normal
Start: 11/09/18
End: 08/31/27
Due: 08/31/28
Phase: N/A
Priority: Normal
Start: 09/13/21
End: 05/31/25
Due: 05/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | NCT05149898 | Zynerba Pharmaceuticals, Inc. | user2@example.com | None | 2020-03-03 | 2022-11-21 | 2023-11-21 | - | - | 2025-07-14 |
| Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) | NCT03614663 | Zynerba Pharmaceuticals, Inc. | user2@example.com | None | 2018-06-12 | 2020-06-14 | 2021-06-14 | - | - | 2025-07-14 |
| Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | NCT03802799 | Zynerba Pharmaceuticals, Inc. | user2@example.com | None | 2018-11-09 | 2027-08-31 | 2028-08-31 | - | - | 2025-07-14 |
| Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome | NCT04977986 | Zynerba Pharmaceuticals, Inc. | user2@example.com | None | 2021-09-13 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |